Skip to main content

Advertisement

SpringerLink
Log in

Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To characterize the population pharmacokinetics of plitidepsin (Aplidin®) in cancer patients.

Methods

A total of 283 patients (552 cycles) receiving intravenous plitidepsin as monotherapy at doses ranging from 0.13 to 8.0 mg/m2 and given as 1- or 24-h infusions every week; 3- or 24-h infusion biweekly; or 1-h infusion daily for 5 consecutive days every 21 days were included in the analysis. An open three-compartment pharmacokinetic model and a nonlinear binding to red blood cells model were used to describe the plitidepsin pharmacokinetics in plasma and blood, respectively, using NONMEM V software. The effect of selected covariates on plitidepsin pharmacokinetics was investigated. Model evaluation was performed using goodness-of-fit plots, posterior predictive check and bootstrap.

Results

Plasma clearance and its between subject variability (%) was 13.6 l/h (71). Volume of distribution at steady-state was calculated to be 4791 l (59). The parameters B max and C 50 of the non-linear blood distribution were 471 μg/l (56) and 41.6 μg/l, respectively. Within the range of covariates studied, age, sex, body size variables, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, creatinine clearance, albumin, total protein, performance status, co-administration of inhibitors or inducers of CYP3A4 and presence of liver metastases were not statistically related to plitidepsin pharmacokinetic parameters. Bootstrap and posterior predictive check evidenced the model was deemed appropriate to describe the time course of plitidepsin blood and plasma concentrations in cancer patients.

Conclusions

The integration of phase I/II pharmacokinetic data demonstrated plitidepsin linear elimination from plasma, dose-proportionality up to 8.0 mg/m2, and time-independent pharmacokinetics. The distribution to red blood cells can be considered linear at doses lower than 5 mg/m2 administered as 3-h or longer infusion. No clinically relevant covariates were identified as predictors of plitidepsin pharmacokinetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rinehart KL (2000) Antitumor compounds from tunicates. Med Res Rev 20:1–27

    Article  PubMed  CAS  Google Scholar 

  2. Brandon EF, Sparidans RW, van Ooijen RD et al (2007) In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs 25:9–19

    Article  PubMed  CAS  Google Scholar 

  3. Adrian TE (2007) Novel marine-derived anti-cancer agents. Curr Pharm Des 13:3417–3426

    Article  PubMed  CAS  Google Scholar 

  4. Broggini M, Marchini SV, Galliera E et al (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17:52–59

    Article  PubMed  CAS  Google Scholar 

  5. Cuadrado A, Garcia-Fernandez LF, Gonzalez L et al (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 278:241–250

    Article  PubMed  CAS  Google Scholar 

  6. Erba E, Bassano L, Di LG et al (2002) Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 86:1510–1517

    Article  PubMed  CAS  Google Scholar 

  7. Garcia-Fernandez LF, Losada A, Alcaide V et al (2002) Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 21:7533–7544

    Article  PubMed  CAS  Google Scholar 

  8. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N et al (2008) Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther 324:1093–1101

    Article  PubMed  CAS  Google Scholar 

  9. Suarez Y, Gonzalez-Santiago L, Zarich N et al (2006) Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content. Mol Pharmacol 70:1654–1663

    Article  PubMed  CAS  Google Scholar 

  10. Taraboletti G, Poli M, Dossi R et al (2004) Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 90:2418–2424

    PubMed  CAS  Google Scholar 

  11. Biscardi M, Caporale R, Balestri F et al (2005) VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 16:1667–1674

    Article  PubMed  CAS  Google Scholar 

  12. Bresters D, Broekhuizen AJ, Kaaijk P et al (2003) In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. Leukemia 17:1338–1343

    Article  PubMed  CAS  Google Scholar 

  13. Celli N, Mariani B, Di CF et al (2004) Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. J Pharm Biomed Anal 34:619–630

    Article  PubMed  CAS  Google Scholar 

  14. Depenbrock H, Peter R, Faircloth GT et al (1998) In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78:739–744

    PubMed  CAS  Google Scholar 

  15. Gonzalez-Santiago L, Suarez Y, Zarich N et al (2006) Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 13:1968–1981

    Article  PubMed  CAS  Google Scholar 

  16. Lobo C, García-Pozo SG, Núñez de Castro I et al (1997) Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 17:333–336

    PubMed  CAS  Google Scholar 

  17. Urdiales JL, Morata P, Núñez de Castro I et al (1996) Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from mediterranean tunicates. Cancer Lett 102:31–37

    Article  PubMed  CAS  Google Scholar 

  18. Straight AM, Oakley K, Moores R et al (2006) Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57:7–14

    Article  PubMed  CAS  Google Scholar 

  19. Faivre S, Chieze S, Delbaldo C et al (2005) Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 23:7871–7880

    Article  PubMed  CAS  Google Scholar 

  20. Jimeno JM (2002) A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13(Suppl 1):S15–S19

    PubMed  CAS  Google Scholar 

  21. Maroun JA, Belanger K, Seymour L et al (2006) Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 17:1371–1378

    Article  PubMed  CAS  Google Scholar 

  22. Yin J (2003) Determination of plasma protein binding properties. PUSA 00147. Pharmamar USA Inc, Cambridge

    Google Scholar 

  23. Casals D (2007) Hepatic microsomal metabolism of 14C aplidine-mass identification of three main metabolites of aplidine. S03/012B-AD.2003.KYMOS, Barcelona, Spain

  24. Beal SL, Sheiner LB (1992) NONMEM users guides. GloboMax, LLC, Hanover

  25. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735–750

    Article  PubMed  CAS  Google Scholar 

  26. Wahlby U, Jonsson EN, Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS Pharm Sci 4:E27

    Article  Google Scholar 

  27. Wahlby U, Matolcsi K, Karlsson MO et al (2004) Evaluation of type I error rates when modeling ordered categorical data in NONMEM. J Pharmacokinet Pharmacodyn 31:61–74

    Article  PubMed  Google Scholar 

  28. Efron B, Tibshirani R (1993) An Introduction to the bootstrap. Chapman & Hall/CRC Press, London/Boca Raton

    Google Scholar 

  29. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192

    Article  PubMed  CAS  Google Scholar 

  30. Bruno R, Vivler N, Vergniol JC et al (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172

    Article  PubMed  CAS  Google Scholar 

  31. Henningsson A, Sparreboom A, Sandstrom M et al (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39:1105–1114

    Article  PubMed  CAS  Google Scholar 

  32. Nguyen L, Chatelut E, Chevreau C et al (1998) Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41:125–132

    Article  PubMed  CAS  Google Scholar 

  33. Periclou AP, Avramis VI (1996) NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 39:42–50

    Article  PubMed  CAS  Google Scholar 

  34. Schleyer E, Kuhn S, Ruhrs H et al (1997) Oral idarubicin pharmacokinetics–correlation of trough level with idarubicin area under curve. Leukemia 11(Suppl 5):S15–S21

    PubMed  CAS  Google Scholar 

  35. Urien S, Rezai K, Lokiec F (2005) Pharmacokinetic modelling of 5-FU production from capecitabine–a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn 32:817–833

    Article  PubMed  CAS  Google Scholar 

  36. Xie R, Mathijssen RH, Sparreboom A et al (2002) Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 20:3293–3301

    Article  PubMed  CAS  Google Scholar 

  37. Perez-Ruixo JJ, Zannikos P, Hirankarn S et al (2007) Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 46:867–884

    Article  PubMed  CAS  Google Scholar 

  38. Maroun JA, Goel R, Stewart DJ et al (2001) Phase I study of Aplidin in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas. In: Proceedings of the American society of clinical oncology, 2001, Abstract #2082. http://www.asco.org

  39. Indiana University School of Medicine Department of Medicine (2008) http://medicine.iupui.edu/flockhart/table.htm

Download references

Acknowledgments

The authors would like to thank the patients, investigators and their medical, nursing and laboratory staff who participated in the clinical trials included in the present study. In particular, we recognize the effort from the laboratory staff of the Mario Negri Institute, who participated in the bioanalytical analysis of plitidepsin samples.

Conflict of interest

The authors disclosure none conflict of interest other than that Arturo Soto-Matos and Bernardo Miguel-Lillo are employees of Pharma Mar SA.

Author information

Authors and Affiliations

  1. Pharmacy and Pharmaceutics Division, Department of Engineering, Faculty of Pharmacy, Miguel Hernández University, Crta. Alicante-Valencia km. 87, 03550, San Juan de Alicante (Alicante), Spain

    Ricardo Nalda-Molina, Belén Valenzuela, Amelia Ramon-Lopez & Juan Jose Perez-Ruixo

  2. Clinical Pharmacology Department, Pharma Mar S.A. Avda. de los Reyes, 1. Pol.Ind. La Mina-Norte, 28770, Colmenar Viejo (Madrid), Spain

    Bernardo Miguel-Lillo & Arturo Soto-Matos

Authors
  1. Ricardo Nalda-Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Belén Valenzuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amelia Ramon-Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernardo Miguel-Lillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arturo Soto-Matos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan Jose Perez-Ruixo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricardo Nalda-Molina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nalda-Molina, R., Valenzuela, B., Ramon-Lopez, A. et al. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects. Cancer Chemother Pharmacol 64, 97–108 (2009). https://doi.org/10.1007/s00280-008-0841-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0841-4

Keywords

Search

Navigation